Financial Data and Key Metrics Changes - The company reported revenues of $112.6 million for Q4 2022, reflecting a 38% year-over-year growth and a sequential growth of 8% [69] - Adjusted net loss for Q4 2022 was $17.9 million, or a loss of $0.59 per share, compared to a loss of $19.1 million in Q3 2022 [51] - Full year 2022 revenues reached $410.9 million, representing a 27% growth compared to 2021 [77] - Gross margin for Q4 was 69.9%, with a full year gross margin of 68.5% [50][77] - Adjusted EBITDA for Q4 was positive at $1.1 million, showing significant improvement year-over-year [79] Business Line Data and Key Metrics Changes - The Zio XT service saw strong demand, with new account openings reaching record levels [69] - Home enrollment accounted for about 20% of volume in Q4 2022 [77] - The Zio AT service continued to grow, although at a slower pace compared to the first nine months of 2022 [69] Market Data and Key Metrics Changes - The company anticipates full year revenue growth of approximately 16% to 18% for 2023, amounting to $475 million to $485 million [53] - Approximately 75% of Medicare and commercial patients eligible for coverage now have a $50 co-pay or less [43] Company Strategy and Development Direction - The company is focusing on expanding into primary care, targeting over 14 million patients with cardiac-related issues annually [42] - A nationwide agreement with One Medical has been established to enhance technology-powered solutions [36] - The company plans to launch the next-generation Zio Monitor in the back half of 2023, which is expected to improve patient experience [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating operational challenges and expects to see improvements in return device rates and AT business performance [58] - The company is optimistic about the early signs of improvement in healthcare staffing challenges experienced in 2022 [73] - Management highlighted the importance of EHR integration for creating stickiness with accounts and driving growth [30] Other Important Information - The company has cleared material weaknesses in its internal control environment, enhancing operational efficiency [52][80] - The anticipated launch of the Zio Watch is expected to provide complementary monitoring solutions [75] Q&A Session Summary Question: Update on 16% to 18% guidance range and challenges faced - Management feels confident about business progress and expects to navigate through growth headwinds effectively [58] Question: Insights on the new sensor's limited launch - Early indicators from the limited launch of the new sensor are positive, with expectations for a broader launch later in the year [61] Question: Status of AT volumes and growth expectations - The AT business is expected to grow around 30%, with confidence in returning to previous growth levels as operational issues are resolved [92]

Revenue Sources and Financial Performance - In 2022, approximately 25% of the company's total revenue was derived from the Medicare program, including Medicare Advantage[128] - The company's international operations currently account for approximately 2% of its revenue for the twelve months ended December 31, 2022, with plans to pursue growth opportunities in the Philippines and the United Kingdom[172] - Revenue from non-contracted third-party commercial payors accounted for approximately 6% of total revenue during the year ended December 31, 2022[204] - Revenue for the year ended December 31, 2022, was $410.9 million, a 27.2% increase from $322.8 million in 2021[373] - Gross profit for 2022 was $281.6 million, compared to $213.6 million in 2021, reflecting a gross margin improvement[373] - The net loss for 2022 was $116.2 million, compared to a net loss of $101.4 million in 2021, resulting in a net loss per share of $3.88[373] - The company incurred net losses of $116.2 million and $101.4 million during fiscal 2022 and 2021, respectively, with an accumulated deficit of $522.2 million as of December 31, 2022[205] Regulatory and Compliance Risks - The company faces risks related to compliance with Medicare regulations, which could lead to penalties or exclusion from the Medicare program, adversely affecting its business and financial condition[128] - The company must maintain enrollment with the Medicare program and accreditation with the Joint Commission to ensure reimbursement from commercial payors[130] - Changes in reimbursement rates by CMS or commercial payors could adversely affect the company's business and operating results[131] - Non-compliance with healthcare regulations could lead to substantial penalties, including civil monetary penalties and loss of revenue from commercial payor contracts[186] - The company is subject to audits and claims reviews by government agencies, which may result in payment delays and claims denials, negatively impacting financial results[146] - The company is subject to legal proceedings and government investigations that could adversely affect its business and financial condition[210] Operational Challenges - The company relies heavily on its Zio Services for revenue, which is expected to account for substantially all revenue for the foreseeable future[138] - Billing for Zio Services is complex and requires substantial resources, which could negatively impact revenue and cash flow[145] - The company is undergoing a transformation of its revenue cycle management function, which may impact revenue and accounts receivable if not executed efficiently[148] - The company faces significant risks associated with international expansion, including regulatory compliance, financial risks, and potential litigation, which could adversely affect future revenue and operations[170] - The company may face challenges in scaling operations and managing growth, which could strain personnel resources and infrastructure, impacting future revenue[177] - The company has experienced significant changes in executive leadership, including the appointment of Quentin S. Blackford as President and CEO in October 2021, which may impact strategic execution[174] Research and Development - The company is in various stages of research and development for new diagnostic screening solutions, but there is no assurance that these will be successfully commercialized[138] - The company is focused on developing new product offerings and enhancements to its Zio Services, but faces challenges in maintaining adequate research and development resources[165] - The company acknowledges that the success of its collaboration with Verily is highly dependent on the efforts and skill sets of both parties, with no assurance of commercial viability[168] Supply Chain and Vendor Risks - The company relies on third-party vendors for components of the Zio Systems, which poses risks related to supply chain disruptions and manufacturing capacity[159] - Any significant delays in the supply of components could impair the ability to meet demand for Zio Services, affecting future revenue and market reputation[162] - The company relies on single-source vendors for critical components, which poses a risk of supply delays[409] - A global semiconductor supply shortage is affecting suppliers that provide PCBAs to the Company, potentially impacting operations[410] Financial Management and Capital Structure - The company has a revolving line of credit of up to $25.0 million and term loans of up to $75.0 million, with $35.0 million outstanding under term loans as of December 31, 2022[243] - The company's total outstanding debt increased to $34.9 million in 2022 from $21.4 million in 2021, reflecting an increase of approximately 63.0%[349] - The company may require additional capital to support business growth, which might not be available on acceptable terms[206] - The company may need to adopt alternative measures such as reducing investments or selling assets if unable to generate sufficient cash flow to service its debt[247] Market and Competitive Landscape - The market for ambulatory cardiac monitoring solutions is highly competitive, with significant competition from both large manufacturers and smaller regional service providers[139] - The competitive landscape for medical devices is dynamic, and failure to innovate could lead to obsolescence and declining revenue as customers turn to competitors[164] - The company faces scrutiny regarding its relationships with healthcare providers, which are essential for the clinical acceptance of its Zio Services[191] Legal and Tax Considerations - Changes in tax laws or their interpretation could adversely affect the company's business and financial condition[214] - The TCJA eliminated the option to immediately deduct research and development expenditures starting in 2022, requiring amortization over five years for domestic and fifteen years for foreign expenditures, potentially impacting cash from operating activities and deferred taxes[215] - The company is subject to examination by the U.S. Internal Revenue Service and other tax authorities, and an increase in effective tax rates could negatively impact its financial condition, operating results, and cash flows[216] Cybersecurity and Data Protection - Cybersecurity risks could compromise confidential data and disrupt business operations, leading to potential liability under various laws and regulations[228] - The company has implemented multiple layers of security measures to protect sensitive information, but remains vulnerable to cyber-attacks and data breaches, which could harm operations and profitability[232] - The company's communications with patients are subject to strict regulations, with potential damages of $500 per violation under the Telephone Consumer Protection Act[196] Impairment and Asset Management - For the year ended December 31, 2022, the Company recorded $23.2 million of long-lived asset impairment charges[418] - The Company tests long-lived assets for impairment annually or when circumstances indicate potential recoverability issues[417] - Goodwill is tested for impairment at least annually, with the annual test completed in the fourth quarter[416]

[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The unaudited condensed consolidated financial statements for the period ended September 30, 2022, detail the company's financial position, operational results, and cash flows, reflecting revenue growth, continued net losses, and significant cash usage [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of September 30, 2022, the company's total assets were **$440.4 million**, a decrease from **$463.0 million** at the end of 2021, primarily due to a reduction in cash and cash equivalents. Total liabilities increased to **$201.2 million** from **$183.5 million**, driven by an increase in noncurrent debt. Consequently, total stockholders' equity declined to **$239.2 million** from **$279.5 million** | Balance Sheet Items (In thousands) | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $71,222 | $127,562 | | Accounts receivable, net | $60,534 | $46,430 | | Total current assets | $285,850 | $305,522 | | Total assets | $440,390 | $462,967 | | **Liabilities & Equity** | | | | Total current liabilities | $83,591 | $87,853 | | Debt, noncurrent portion | $34,931 | $9,690 | | Total liabilities | $201,166 | $183,452 | | Total stockholders' equity | $239,224 | $279,515 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the third quarter of 2022, revenue grew to **$103.9 million** from **$85.4 million** in Q3 2021, with gross profit increasing to **$70.9 million**. However, the company reported a net loss of **$21.5 million** for the quarter. For the nine months ended September 30, 2022, revenue was **$298.3 million**, up from **$241.0 million** year-over-year, but the net loss widened to **$96.0 million** from **$68.9 million**, partly due to **$26.6 million** in impairment and restructuring charges | Metric (In thousands) | Q3 2022 | Q3 2021 | | :--- | :--- | :--- | | Revenue, net | $103,875 | $85,432 | | Gross profit | $70,921 | $56,148 | | Loss from operations | $(21,086) | $(23,282) | | Net loss | $(21,451) | $(23,731) | | Net loss per share | $(0.71) | $(0.81) | | Metric (In thousands) | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | | Revenue, net | $298,304 | $241,021 | | Gross profit | $202,925 | $162,284 | | Impairment and restructuring charges | $26,608 | $0 | | Loss from operations | $(93,086) | $(67,744) | | Net loss | $(95,957) | $(68,870) | | Net loss per share | $(3.22) | $(2.35) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the nine months ended September 30, 2022, net cash used in operating activities was **$35.6 million**, an increase from **$24.7 million** in the prior year period. Net cash used in investing activities was **$44.3 million**, a significant shift from **$132.4 million** provided by investing activities in 2021. Net cash provided by financing activities was **$23.6 million**, primarily from new debt proceeds, compared to a **$28.9 million** use of cash in the prior year. This resulted in a net decrease in cash and cash equivalents of **$56.3 million** | Cash Flow Activity (In thousands) | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(35,588) | $(24,708) | | Net cash (used in) provided by investing activities | $(44,320) | $132,397 | | Net cash provided by (used in) financing activities | $23,568 | $(28,946) | | **Net (decrease) increase in cash** | **$(56,340)** | **$78,743** | [Notes to Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail significant accounting policies, highlighting risks from macroeconomic factors, Medicare reimbursement uncertainty, and the impact of CPT code transitions, alongside details on impairment charges and new debt agreements - The company faces significant uncertainty regarding Medicare reimbursement. CMS did not establish national pricing for key CPT codes for 2022, leaving it to regional MACs. On November 2, 2022, CMS released its 2023 final rule, which the company interprets as reflecting national reimbursement rates of **$224** for CPT code 93247 and **$213** for CPT code 93243[40](index=40&type=chunk)[42](index=42&type=chunk)[43](index=43&type=chunk) - Revenue from CMS accounted for **26%** of total revenue in Q3 2022 and **24%** for the first nine months of 2022, a significant increase from **15%** and **14%** in the respective periods of 2021[61](index=61&type=chunk) - In February 2022, the company initiated a restructuring plan, resulting in **$3.4 million** in severance costs and a **$23.2 million** impairment charge on its San Francisco headquarters' right-of-use asset and related property[94](index=94&type=chunk) - On March 28, 2022, the company amended its loan agreement with SVB, securing a new term loan facility of up to **$75.0 million**. It borrowed **$35.0 million** at closing, using part of the proceeds to repay an existing **$18.5 million** balance[112](index=112&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=33&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's performance, noting revenue growth driven by Zio service volume and CMS rates, but a widening net loss due to increased expenses and one-time charges, alongside details on liquidity and debt facilities [Results of Operations](index=36&type=section&id=Results%20of%20Operations) Revenue for Q3 2022 increased **22%** year-over-year to **$103.9 million**, driven by higher Zio service volume and better CMS rates. Gross margin improved to **68%** from **66%**. Operating expenses rose **16%**, with R&D up **32%** and SG&A up **14%**. For the nine-month period, revenue grew **24%** to **$298.3 million**, but total operating expenses increased **29%**, including **$26.6 million** in impairment and restructuring charges, leading to a wider loss from operations | Metric (In thousands) | Q3 2022 | Q3 2021 | % Change | | :--- | :--- | :--- | :--- | | Revenue | $103,875 | $85,432 | 22% | | Gross Profit | $70,921 | $56,148 | 26% | | Gross Margin | 68% | 66% | - | | R&D Expenses | $11,448 | $8,685 | 32% | | SG&A Expenses | $80,559 | $70,745 | 14% | | Loss from Operations | $(21,086) | $(23,282) | 9% | - The nine-month results included **$23.2 million** in impairment charges related to the San Francisco headquarters and **$3.4 million** in severance costs from a restructuring plan, which were not present in the prior year[180](index=180&type=chunk) [Liquidity and Capital Expenditures](index=38&type=section&id=Liquidity%20and%20Capital%20Expenditures) As of September 30, 2022, the company had **$71.2 million** in cash and cash equivalents and **$132.3 million** in short-term investments. Management believes it has adequate liquidity for the next 12 months, supported by available term loan facilities of **$40.0 million** and a **$25.0 million** revolving credit line. Net cash used in operations for the first nine months of 2022 was **$35.6 million**, primarily due to a net loss of **$96.0 million**, offset by non-cash charges, and an increase in accounts receivable - The company's cash and cash equivalents decreased by **$56.3 million** during the first nine months of 2022[188](index=188&type=chunk) - Cash used in operating activities increased to **$35.6 million** for the nine months ended Sep 30, 2022, from **$24.7 million** in the same period of 2021, largely due to an increase in accounts receivable[189](index=189&type=chunk)[191](index=191&type=chunk) - The company secured a new term loan facility of up to **$75.0 million** and an extended **$25.0 million** revolving credit line through March 2027, enhancing its liquidity position[198](index=198&type=chunk)[199](index=199&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are related to interest rate and foreign currency exchange rate sensitivity. Interest rate risk stems from its cash equivalents, investments, and variable-rate debt. Foreign currency risk arises from transactions in British Pound Sterling. Management does not consider these risks to be material and states that a hypothetical **10%** change in interest rates would not have had a material impact on the financial statements - The company holds **$203.5 million** in cash, cash equivalents, and investments, which are subject to interest rate risk, though historical fluctuations have not been significant[204](index=204&type=chunk) - The outstanding debt of **$34.9 million** carries a variable interest rate tied to the Prime Rate, exposing the company to interest rate fluctuations[206](index=206&type=chunk) - Foreign exchange risk is primarily from transactions in British Pound Sterling but is not considered material as of September 30, 2022[207](index=207&type=chunk) [Item 4. Controls and Procedures](index=42&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective as of September 30, 2022, due to a material weakness in the control environment, with remediation efforts underway including key personnel hires - The CEO and CFO concluded that disclosure controls and procedures were not effective as of September 30, 2022, due to a continuing material weakness in internal controls over financial reporting[210](index=210&type=chunk) - The material weakness stems from not maintaining an effective control environment, specifically a failure to maintain a sufficient number of professionals with appropriate accounting and internal control expertise[211](index=211&type=chunk) - Remediation efforts include hiring an IT Compliance Director (Jan 2022), a Chief Risk Officer (May 2022), a Senior Director of Internal Audit (June 2022), and a new Chief Financial Officer (Aug 2022) to strengthen the control environment[212](index=212&type=chunk)[218](index=218&type=chunk) [PART II. OTHER INFORMATION](index=44&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in a putative securities class action lawsuit filed in February 2021, which was dismissed by the court in March 2022 but is currently under appeal by the plaintiff. Additionally, the company received grand jury subpoenas from the U.S. Attorney's Office in March and October 2021 related to communications with the FDA and its products, and is cooperating with the request - A securities class action lawsuit alleging violations of the Exchange Act was dismissed on March 31, 2022, but the plaintiff filed a notice of appeal on April 29, 2022. The company believes the action is without merit[220](index=220&type=chunk) - The company received grand jury subpoenas from the U.S. Attorney's Office for the Northern District of California in March and October 2021 requesting information related to FDA communications and products. The company is cooperating fully[221](index=221&type=chunk)[105](index=105&type=chunk) [Item 1A. Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) The company outlines significant risks including reimbursement uncertainty, macroeconomic impacts, a history of net losses, market competition, intellectual property litigation, regulatory changes, and recent management turnover - **Reimbursement Risk:** Changes in CMS and MAC reimbursement rates, such as the lower-than-historical rates from Novitas Solutions, could negatively impact profitability and influence commercial payors to reduce their rates[223](index=223&type=chunk)[244](index=244&type=chunk)[247](index=247&type=chunk) - **Operational & Financial Risk:** The company has a history of net losses which are expected to continue. The business is also adversely impacted by the COVID-19 pandemic and macroeconomic factors affecting supply chains, costs, and patient/hospital demand[223](index=223&type=chunk)[225](index=225&type=chunk)[231](index=231&type=chunk) - **Market & Competitive Risk:** The business depends on broad physician adoption of the Zio service. The ambulatory cardiac monitoring market is highly competitive, with large, well-resourced competitors that could develop more effective or accepted products[223](index=223&type=chunk)[232](index=232&type=chunk)[281](index=281&type=chunk) - **Management & Control Risk:** The company has recently experienced significant management turnover, including a new CEO, CFO, and CCO, which creates uncertainty. A material weakness in internal control over financial reporting also persists[296](index=296&type=chunk)[297](index=297&type=chunk)[327](index=327&type=chunk) - **Regulatory Risk:** The company must comply with extensive regulations from the FDA and CMS. Failure to maintain regulatory clearances, such as for the Zio AT monitor, or comply with IDTF rules could harm commercial operations[352](index=352&type=chunk)[356](index=356&type=chunk)[278](index=278&type=chunk) [Item 2-6. Other Information](index=83&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Under these items, the company reports no unregistered sales of equity securities, no defaults upon senior securities, and no mine safety disclosures. Item 5 provides general corporate information, including the company's website and social media channels for investor communication. Item 6 refers to the exhibit index filed with the report - The company reported no unregistered sales of equity securities or use of proceeds for the period[387](index=387&type=chunk) - The company notes that it uses its investor relations website, press releases, SEC filings, and social media channels like Facebook and Twitter to communicate material financial information[390](index=390&type=chunk)

Financial Data and Key Metrics Changes - Revenue for Q3 2022 increased by 22% year-over-year, reaching $103.9 million, and was up 2% sequentially [11][31] - Adjusted EBITDA was negative $2.6 million, an improvement of $2.3 million compared to Q2 2022 and $6.1 million compared to Q3 2021 [36] - Net loss for the quarter was $21.5 million, or a loss of $0.71 per share, compared to a loss of $23.9 million or $0.80 per share in Q2 2022 [35] Business Line Data and Key Metrics Changes - Registration volumes increased by 22% year-over-year, marking the strongest registration growth of the year [11] - Received device rate was 1 to 2 percentage points lower than historical averages, impacting revenue realization [12][23] - New store accounts opened accounted for approximately half of the year-over-year growth, with home enrollment making up about 20% of volume [32] Market Data and Key Metrics Changes - The company anticipates a reduction in revenue guidance for the full year to a range of $407 million to $411 million, reflecting a growth of approximately 26% to 27% year-over-year, down from prior guidance of 29% to 30% [22] - The company is seeing strong demand for its Zio service, with healthy registration rates despite staffing challenges [13][28] Company Strategy and Development Direction - The company is focused on enhancing its Zio AT product to grow market share in the MCT space and is committed to developing innovative solutions [42][28] - The company continues to invest in mid and long-term initiatives leveraging its technology platform and expanding into new geographies and markets [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory of the ACM market and the company's ability to capture market share [28] - Despite a reduction in revenue expectations, management remains encouraged by the underlying momentum in the business and the demand for the Zio service [41][27] Other Important Information - The company issued a customer advisory notice related to the Zio AT product, which is expected to impact growth in the fourth quarter [25] - The gross margin for Q3 was 68.3%, a slight decrease from the previous quarter but an improvement from the same period last year [33] Q&A Session Summary Question: Guidance and impacts on revenue - Management attributed the revenue guidance reduction to staffing and capacity challenges, with a significant impact from the lower returned device rate [44][46] Question: Changes since Analyst Day - Management noted that while they were optimistic at the time of the Analyst Day, the received device rate did not recover as expected, leading to the revised guidance [52][55] Question: Device return rates and Home Enrollment - Management clarified that the received device rate for Home Enrollment is typically 2 to 3 times lower than in-clinic rates, and they plan to implement strategies to improve this [60][62] Question: Commercial payer negotiations - Management indicated that there are no significant changes expected in commercial payer negotiations for 2023, maintaining a low single-digit pricing pressure outlook [72] Question: New product launches - Management expects the Zio monitor to launch more fully in mid-2023, with enhancements to the Zio AT product anticipated for early 2024 [88][89]

iRHYTHM® Investor Presentation August 2022 Safe Harbor Certain data in this presentation was obtained from various external sources, and neither "iRhythm" or the "Company" nor its affiliates or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy of that data or undertakes to update such data after the date of this presentation. Such data involves risks and uncerta ...

iRhythm Technologies, Inc. (NASDAQ:IRTC) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor Relations Quentin Blackford - President and Chief Executive Officer Doug Devine - Chief Operating Officer and Chief Financial Officer Dan Wilson - EVP of Corporate Strategy and Development Conference Call Participants Calvin Chu - Morgan Stanley Allen Gong - JPMorgan Joanne Wuensch - Citi Brandon Vazquez - William Blair David Rescott - Truist Sec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ Form 10-Q _______________________________________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 ____________ ...

iRhythm Technologies, Inc. (NASDAQ:IRTC) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Quentin Blackford - President and Chief Executive Officer Douglas Devine - COO & CFO Dan Wilson - EVP of Corporate Strategy and Development Conference Call Participants Allen Gong - JP Morgan Maggie Boeye - William Blair David Rescott - Truist Securities William Plovanic - Canaccord Genuity Marie Thibault - BTIG Suraj Kalia - Oppenheimer Operator Thank you all for participating in today's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ Form 10-Q _______________________________________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 ___________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ FORM 10-K ________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...